Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control

  title={Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control},
  author={Yogendra Keche},
  journal={Journal of Pharmacy and Bioallied Sciences},
  pages={148 - 150}
  • Y. Keche
  • Published 1 April 2010
  • Medicine, Biology
  • Journal of Pharmacy and Bioallied Sciences
Food and Drug Administration (FDA) approved bromocriptine mesylate, a quick release formulation, 0.8 mg tablets, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Bromocriptine products were previously approved by the FDA for the treatment of pituitary tumors and Parkinson's disease. Bromocriptine is thought to act on circadian neuronal activities within the hypothalamus to reset abnormally elevated hypothalamic drive for increased plasma… 
Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus
While HOMC and HbA1c levels decreased significantly after 6 months of treatment with BROM-QR in patients with T2DM, serum levels of hs-CRP, total cholesterol and triglyceride did not significantly change.
Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes.
The findings suggest potential use of dietary constituents as a complementary approach to pharmacotherapy in the prevention and/or management of diabetes, but further research is necessary to identify the active components and evaluate their efficacy and safety.
Application of Clinical Judgment and Guidelines to Achieving Glycemic Goals in Type 2 Diabetes: Focus on Pharmacologic Therapy
How diabetes guidelines evolved, their move toward personalization of therapy, and their effective use in clinical practice are discussed and guidance on assessing recommendations made by the latest diabetes guidelines for pharmacotherapy is provided.
The importance of synthetic drugs for type 2 diabetes drug discovery
The authors specifically evaluate two newer classes of anti-diabetic agents: dipeptidyl peptidase IV (DPP-4) and sodium-glucose transporter-2 (SGLT2) and present information on newer synthetic compounds.
Red carpeting the newer antidiabetics
  • D. Gude
  • Biology, Medicine
    Journal of pharmacology & pharmacotherapeutics
  • 2012
A review of the newer drugs targeting various aspects in the management of diabetes is presented and indicates an urgent need for newer and better treatment options.
Modulation of indole ring annulation in ergoline template: chemistry, receptor binding and in vivo pharmacology with 6-OHDA model of Parkinson’s disease
Both compounds 16 and 20 showed antiparkinsonian activity in a dose-dependant manner and slightly longer duration of action as compared to apomorphine, which delays l-dopa treatment in PD.
Bromocriptine treatment at the end of lactation prevents hyperphagia, higher visceral fat and liver triglycerides in early‐weaned rats at adulthood
The treatment with BRO can preclude some deleterious effects of the NPEW model, which prevented the development of overweight and its comorbidities.
Effect of Bromocriptine and Nano-Bromocriptine on Egg Quality Parameters of Late Laying Hens
Corresponding Author: Ahmed Dawod Department of Husbandry and Animal Wealth Development, Faculty of Veterinary Medicine, University of Sadat City, Menofia, Egypt Email: Abstract:
Ergot Alkaloids: A Review on Therapeutic Applications
Structural resemblance with various neurotransmitters allows them to interact with a number of receptors which makes them work on different target thus designing new ergot based drugs with receptor subtype selectivity will be more effective.